Help us: Donate
Follow us on:
×

Menu

Back

Tag: Aubrey de Grey

Crypto is an important source of support for longevity tech.
VitaDAO, the world’s first decentralized intellectual property collective, hosted a discussion and AMA on Youtube yesterday. The event featured guests Dr. Aubrey de Grey from SENS Research Foundation and Vitalik Buterin, one of the co-founders of Ethereum. Introducing Aubrey de Grey and Vitalik Buterin Dr. Aubrey de Grey is a British biomedical gerontologist who researched...
SenNet
The National Institute of Health is going all-in on cellular senescence with its recently announced SenNet program. We asked two of the leading experts in aging research to weigh in on this initiative. The NIH takes notice  Cellular senescence has been at the forefront of longevity researchers' minds for quite some time now, as it...
Longevity Therapeutics banner
We continue our coverage of Longevity Therapeutics 2021 and bring you part 2 of day 1. Read the first article of the series here. Dr. Steven Braithwhite - Chief Scientific Officer, Alkahest Steven Braithwhite from Alkahest gave an update on the company’s ongoing clinical trials. Alkahest has been sifting plasma proteome in search for proteins...
Aubrey de Grey Presentation
The Oxford Society for Ageing and Longevity has recently started hosting online webinars with some of the leading figures in the field. On November 25th, Dr. Aubrey de Grey from SENS Research Foundation gave a talk that be began with his usual discussion, with which the community is very familiar, about what aging is and...
Investment
More and more investors are starting to get interested in technologies that are being developed to slow or even reverse aging as therapies are starting to reach human trials. Recently, I attended the Longevity Investors Conference to learn more about investments being made towards anti-aging research. A shift towards doing something about aging The current...
Dr. Aubrey de Grey thumbnail
In his keynote speech at Ending Age-Related Diseases 2020, Dr. Aubrey de Grey of SENS Research Foundation discusses the current state of the rejuvenation biotechnology industry in the context of the current pandemic. He mentions the failure of Unity Biotechnology's Phase 2 clinical trial for osteoarthritis, COVID-19 and the elderly immune system, the current popularization...